Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Ji-Bin Li, Xiong-Wen Tang, Jun-Sheng Peng, Zhi-Wei Zhou, Rui-Hua Xu, Feng Wang
Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is under investigation. In this randomized, open-label, phase 2 study (NEOSUMMIT-01), patients with resectable gastric or gastro-esophageal junction cancer clinically staged as cT3-4aN + M0 were randomized (1:1) to receive either three preoperative and five postoperative 3-week cycles of SOX/XELOX (chemotherapy group, n = 54) or PD-1 inhibitor toripalimab plus SOX/XELOX, followed by toripalimab monotherapy for up to 6 months (toripalimab plus chemotherapy group, n = 54)...
February 2024: Nature Medicine